Abstract
Tumor cell growth, even in advanced stages of ovarian cancer, is nearly always restricted to the peritoneal cavity; therefore, repeated intraperitoneal injections of oligodeoxynucleotides containing dinucleotides with unmethylated CpG motifs (CpG-ODN) recruiting and activating innate effector cells throughout the abdominal cavity to the tumor site might control tumor cell growth and ascites formation. After a single CpG-ODN treatment, in IGROV-1 ovarian tumor ascites-bearing athymic mice, the number of tumor cells declined rapidly and markedly, and ascites volumes declined shortly after treatment (5h), increasing thereafter at a slower rate than in controls. When administered every 7 days for 4 weeks, CpG-ODN had only a marginal effect on survival time, whereas administration 5 days/wk for 3 or 4 weeks led to a significantly increased survival time as compared with controls (P
| Original language | English |
|---|---|
| Pages (from-to) | 8-15 |
| Number of pages | 8 |
| Journal | Journal of Immunotherapy |
| Volume | 33 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jan 2010 |
Fingerprint
Keywords
- Antitumor activity
- Ascites
- CpG-ODN
- Orthotopic model
- Ovarian cancer
ASJC Scopus subject areas
- Immunology
- Immunology and Allergy
- Cancer Research
- Pharmacology
Cite this
Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN. / De Cesare, Michelandrea; Sfondrini, Lucia; Campiglio, Manuela; Sommariva, Michele; Bianchi, Francesca; Perego, Paola; Van Rooijen, Nico; Supino, Rosanna; Rumio, Cristiano; Zunino, Franco; Pratesi, Graziella; Tagliabue, Elda; Balsari, Andrea.
In: Journal of Immunotherapy, Vol. 33, No. 1, 01.2010, p. 8-15.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Ascites regression and survival increase in mice bearing advanced-stage human ovarian carcinomas and repeatedly treated intraperitoneally with CpG-ODN
AU - De Cesare, Michelandrea
AU - Sfondrini, Lucia
AU - Campiglio, Manuela
AU - Sommariva, Michele
AU - Bianchi, Francesca
AU - Perego, Paola
AU - Van Rooijen, Nico
AU - Supino, Rosanna
AU - Rumio, Cristiano
AU - Zunino, Franco
AU - Pratesi, Graziella
AU - Tagliabue, Elda
AU - Balsari, Andrea
PY - 2010/1
Y1 - 2010/1
N2 - Tumor cell growth, even in advanced stages of ovarian cancer, is nearly always restricted to the peritoneal cavity; therefore, repeated intraperitoneal injections of oligodeoxynucleotides containing dinucleotides with unmethylated CpG motifs (CpG-ODN) recruiting and activating innate effector cells throughout the abdominal cavity to the tumor site might control tumor cell growth and ascites formation. After a single CpG-ODN treatment, in IGROV-1 ovarian tumor ascites-bearing athymic mice, the number of tumor cells declined rapidly and markedly, and ascites volumes declined shortly after treatment (5h), increasing thereafter at a slower rate than in controls. When administered every 7 days for 4 weeks, CpG-ODN had only a marginal effect on survival time, whereas administration 5 days/wk for 3 or 4 weeks led to a significantly increased survival time as compared with controls (P
AB - Tumor cell growth, even in advanced stages of ovarian cancer, is nearly always restricted to the peritoneal cavity; therefore, repeated intraperitoneal injections of oligodeoxynucleotides containing dinucleotides with unmethylated CpG motifs (CpG-ODN) recruiting and activating innate effector cells throughout the abdominal cavity to the tumor site might control tumor cell growth and ascites formation. After a single CpG-ODN treatment, in IGROV-1 ovarian tumor ascites-bearing athymic mice, the number of tumor cells declined rapidly and markedly, and ascites volumes declined shortly after treatment (5h), increasing thereafter at a slower rate than in controls. When administered every 7 days for 4 weeks, CpG-ODN had only a marginal effect on survival time, whereas administration 5 days/wk for 3 or 4 weeks led to a significantly increased survival time as compared with controls (P
KW - Antitumor activity
KW - Ascites
KW - CpG-ODN
KW - Orthotopic model
KW - Ovarian cancer
UR - http://www.scopus.com/inward/record.url?scp=74349104485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74349104485&partnerID=8YFLogxK
U2 - 10.1097/CJI.0b013e3181affaa7
DO - 10.1097/CJI.0b013e3181affaa7
M3 - Article
C2 - 19952960
AN - SCOPUS:74349104485
VL - 33
SP - 8
EP - 15
JO - Journal of Immunotherapy
JF - Journal of Immunotherapy
SN - 1053-8550
IS - 1
ER -